FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Seroquel | pharma earnings | AstraZeneca

AZ agrees to pay $520M in Seroquel probe

Tools

AstraZeneca posted strong third-quarter numbers and boosted its full-year forecast by a whopping 40 cents per share. But one of the biggest pieces of news to come out of the company's Q3 report is a $520 million tentative agreement with the U.S. Attorney's Office in Philadelphia. Like several other drugmakers who've announced big settlements this year, AstraZeneca was facing a probe into alleged off-label marketing of a drug. In this case, the antipsychotic Seroquel.

AstraZeneca says it has agreed in principle to pay $520 million to end the probes, with negotiations ongoing to finalize the civil settlements and a corporate integrity agreement. Company executives declined to provide more details about the investigation, beyond the fact that off-label Seroquel marketing allegations were part of it.

Now, $520 million pales next to Eli Lilly's $1.4 billion settlement related to mismarketing of Zyprexa, one of Seroquel's direct rivals in the antipsychotic realm. And it really seems to shrink compared with Pfizer's record-setting $2.3 billion settlement of claims that it mismarketed a handful of meds, including the now-withdrawn painkiller Bextra. Still, the AZ deal involves a big chunk of change, and the company had to increase its legal set-aside to $538 million.

In other Q3 news, pandemic flu was kind to the drugmaker, helping to propel profits upward by 22 percent to $2.12 billion. Plus, the company anticipates the kindness to continue, so it raised its full-year earnings forecast to a maximum of $6.40 from its previous top of $6. And during a quarter when some other Big Pharmas posted profits growth despite sales stagnation, AZ revenues grew by 5.5 percent, helped by strong Crestor sales and forestalled generic competition.

- see the AstraZeneca release
- check out the news from the Wall Street Journal
- see the Associated Press story

Related Articles:
AZ outlined 'weight-neutral' Seroquel pitch
Could Seroquel liability suits be a bust?
Note to AZ: Cut 500, grow EPS by 5 cents
AZ looks to auto plants for efficiency gurus

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about AstraZeneca   Seroquel   pharma earnings  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.